Takeda Pharmaceuticals
The absence of product recalls is not the absence of exposure.
Since Takeda Pharmaceuticals’s last U.S. recall in November 2018, the organization has operated without a further FDA event. While periods of stability are hard earned, a broader review of pharmaceutical recall activity reveals that risk often remains dormant long before it becomes visible.
Product safety events remain an inherent reality of the industry, capable of emerging without warning and attracting immediate scrutiny from regulators, healthcare professionals, and patients alike.
In these moments, your response defines the brand.
Rising recall activity. Escalating consequences.
U.S. pharmaceutical recall activity has remained consistently elevated over the past five years. While annual volumes have fluctuated, the broader trend points to a sustained level of industry exposure rather than a temporary increase.
For Takeda Pharmaceuticals, this environment warrants continued vigilance. Regulatory scrutiny is intensifying as the FDA and policymakers explore expanded authority over recall processes and enforcement. Expectations for speed, transparency, governance, and stakeholder communication continue to rise.
The result is a more demanding operating environment where Takeda Pharmaceuticals will be judged not only by the quality of your products, but by the effectiveness of your response when issues emerge.
The anomalous spike in 2023 was driven by a single, exceptional sterility incident identified through FDA inspection at a manufacturing facility – resulting in nearly 100 events. Excluding this outlier it reveals a more instructive reality: recall activity persists at scale, year after year, rather than fluctuating over time.
A broader risk landscape facing Takeda Pharmaceuticals.
Pharmaceutical recalls are rarely driven by a single point of failure, they emerge across a wide range of risk categories, creating a persistent state of exposure. This breadth is not new. What has changed is the frequency with which these risks continue to surface and the speed at which organisations must respond when they do.
For Takeda Pharmaceuticals, the challenge is not predicting which category may trigger a future event, but in maintaining readiness across the full spectrum of potential scenarios.
What Takeda Pharmaceuticals’s product recall record reveals.
Takeda Pharmaceuticals has not experienced a U.S. FDA recall since November 2018. While this reflects a sustained period of operational stability, a ten-year analysis of 939 pharmaceutical manufacturers reveals an important trend.
Longer periods without a recall are typically followed by higher levels of subsequent recall activity. Manufacturers with seven to eight recall-free years experience more than two events on average when recall activity resumes, compared with 1.39 events among those with only one to two recall-free years.
For Takeda Pharmaceuticals, this offers an important perspective. Extended periods of stability do not necessarily lead to isolated recall events. Organizations emerging from these longer periods often face multiple events in quick succession once recall activity resumes.
Maintaining recall readiness therefore remains just as important during periods of stability as it does during periods of heightened activity.
What follows stability matters most for Takeda Pharmaceuticals.
The analysis reveals a second pattern. Pharmaceutica manufacturers emerging from longer periods without recalls not only experience higher levels of subsequent recall activity, but are also more likely to face large-scale events.
organisations returning after seven or more years without a recall are 65% more likely to experience an event impacting more than one million units than those returning after one or two years.
For Takeda Pharmaceuticals, this adds an important dimension to the risk profile. A period of long stability may reduce the frequency of disruption, but it does not necessarily reduce the scale of the challenge when recall activity returns.
In this context, preparedness is not simply about maintaining compliance. It is about ensuring Takeda Pharmaceuticals can respond effectively to high-consequence events capable of attracting significant regulatory scrutiny, operational disruption, and stakeholder attention.
The FDA expects recall readiness before it is needed
The FDA’s guidance, Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C, is founded on a simple premise: manufacturers should be prepared to execute a recall before a product safety issue emerges.
To support this objective, the agency encourages organisations to maintain trained recall teams, robust distribution records, established communication procedures, and, where appropriate, conduct exercises that validate recall readiness.
For Takeda Pharmaceuticals, this reinforces an important reality. Recall readiness is not measured when an event occurs. It is established during the periods of stability that precede it. As the FDA’s expectations continue to focus on speed, control, and effectiveness, the organizations best positioned to manage future events are often those that have spent the greatest time preparing for them.
Protecting the pharmaceutical industry for 30+ years.
Pharmaceutical manufacturers operate in an environment of increasing complexity, global supply interdependence and heightened regulatory scrutiny, where product safety, precision and traceability must be delivered with absolute consistency.
Since 1995, Sedgwick has supported leading pharmaceutical companies through periods of heightened recall exposure — scaling patient and clinician engagement, strengthening regulatory compliance and safeguarding trust when it matters most.
From the first notification through to event close-out, we execute recalls with proven systems designed to minimize disruptions, protect operations, and strengthen brand integrity.
Proven recall leadership:
- Global delivery at scale: 150+ countries and 50+ languages supported
- Depth of experience: 8,000+ recall and remediation programmes successfully managed
- Proven market impact: 500M+ products safely removed from the market worldwide
- Established heritage: 30+ years of disciplined, regulator-aligned recall leadership
When a nationwide controlled substance recall triggered immediate regulatory and operational pressure
A recall involving 2 million Lorazepam blister packs rapidly escalated into a high-pressure regulatory event.
Following assay and impurity concerns, urgent action was required across pharmacies and healthcare providers nationwide. As a Schedule IV controlled substance, the recall demanded strict FDA and DEA compliance, detailed reconciliation and secure chain-of-custody controls.
Operational complexity intensified further as the recall expanded from 74 direct accounts to more than 2,200 downstream consignees, while product data had to be captured at the individual blister pack level.
Recognizing the scale and scrutiny of the event, the manufacturer engaged Sedgwick Recall to help restore control and support compliant execution.
Solution
The result
A conversation, when it’s useful
Every recall is different, but the pressures medical device manufacturers face are remarkably consistent. If you are considering how Takeda Pharmaceuticals would manage stakeholder communication, operational surge, global logistics and regulatory expectations during a high-visibility event, a short conversation can help clarify what recall readiness looks like in practice.
When the time is right, we’re here. Request an introductory conversation with Wayne.
Wayne Mitchell
Director of Business Development
Wayne brings more than 25 years of experience advising manufacturers on product safety, recall preparedness, and risk management. He helps organisations navigate complex product-related challenges, strengthening their ability to respond effectively when consumer safety, regulatory compliance, and brand reputation are at stake.
Throughout his career, Wayne has partnered with organisations to develop robust recall and incident response capabilities, supporting the governance, planning, and cross-functional coordination required during critical product safety events. His experience spans global market, providing valuable perspective on evolving regulatory expectations and stakeholder scrutiny across jurisdictions.
His expertise spans product safety governance, recall readiness, crisis management, and response strategy, helping organisations mitigate risk, protect consumers, and maintain stakeholder confidence throughout the product lifecycle.
Get deeper insights with our Recall Index
For more than a decade, Sedgwick’s Recall Index report has set the benchmark for product safety intelligence — combining rigorous data analysis with an unbiased perspective on the emerging trends shaping the pharmaceutical risk landscape.
The latest edition examines the regulatory scrutiny, post-market realities and operational pressures influencing drug safety and recall activity, offering essential insight into how risk is evolving in 2026.
Download your copy now and discover why the Recall Index is trusted by pharmaceutical safety and risk leaders in more than 100 countries.
